US4210478A
(en)
*
|
1973-05-08 |
1980-07-01 |
International Paper Company |
Method of making a catheter
|
US3959429A
(en)
*
|
1975-02-03 |
1976-05-25 |
International Paper Company |
Method of making a retention catheter and molding a tip thereon
|
US3985601A
(en)
*
|
1975-05-05 |
1976-10-12 |
Quantum, Inc. |
Method for producing a balloon type catheter having a smooth continuous outer surface
|
US4361152A
(en)
*
|
1975-05-27 |
1982-11-30 |
The Kendall Company |
Catheter
|
US4055187A
(en)
*
|
1976-08-05 |
1977-10-25 |
The Kendall Company |
Catheter with improved balloon assembly
|
US4188954A
(en)
*
|
1976-08-05 |
1980-02-19 |
The Kendall Company |
Catheter with improved balloon assembly
|
US4082114A
(en)
*
|
1977-01-28 |
1978-04-04 |
The Trane Company |
Valve assembly for use in an air distribution system
|
FR2386406A1
(fr)
*
|
1977-04-08 |
1978-11-03 |
Technological Supply |
Procede pour la fabrication d'un catheter a ballonnet
|
US4168710A
(en)
*
|
1977-08-10 |
1979-09-25 |
The Kendall Company |
Balloon cuff and catheter assembly
|
US4143651A
(en)
*
|
1977-11-03 |
1979-03-13 |
The Kendall Company |
Catheter
|
US4222384A
(en)
*
|
1977-11-09 |
1980-09-16 |
Biomedical Engineering Associates, Inc. |
Catheter
|
US4284459A
(en)
*
|
1978-07-03 |
1981-08-18 |
The Kendall Company |
Method for making a molded catheter
|
DE2837813C3
(de)
*
|
1978-08-30 |
1981-08-20 |
Willy Rüsch GmbH & Co KG, 7053 Kernen |
Verfahren zum Herstellen eines medizinischen Tubus oder Katheters
|
US4251305A
(en)
*
|
1978-11-01 |
1981-02-17 |
Baxter Travenol Laboratories, Inc. |
Method of radiant heat sealing of a balloon onto a catheter employing tinted shrink tubing
|
US4445890A
(en)
*
|
1980-05-05 |
1984-05-01 |
The Kendall Company |
Catheter
|
US4447228A
(en)
*
|
1980-05-05 |
1984-05-08 |
The Kendall Company |
Catheter
|
US4445891A
(en)
*
|
1980-05-05 |
1984-05-01 |
The Kendall Company |
Catheter
|
FR2513566A1
(fr)
*
|
1981-09-29 |
1983-04-01 |
Matburn Holdings Ltd |
Procede pour fixer ensemble les matieres plastiques et le caoutchouc
|
FR2521014B1
(fr)
*
|
1982-02-05 |
1988-06-03 |
Matburn Holdings Ltd |
Instrument chirurgical tubulaire, notamment catheter de thrombectomie
|
DE3438131C2
(de)
*
|
1984-10-18 |
1986-08-21 |
Werner Dr.med. 4330 Mülheim Schubert |
Vorrichtung zur Beseitigung von Konkrementen
|
US4787892A
(en)
*
|
1984-12-18 |
1988-11-29 |
The Kendall Company |
Nephrostomy catheter with formed tip
|
US4636272A
(en)
*
|
1985-02-19 |
1987-01-13 |
Cordis Corporation |
Process for thermally bonding plastic tubes
|
US4782834A
(en)
*
|
1987-01-06 |
1988-11-08 |
Advanced Cardiovascular Systems, Inc. |
Dual lumen dilatation catheter and method of manufacturing the same
|
US4861337A
(en)
*
|
1988-03-02 |
1989-08-29 |
Sherwood Medical Company |
Collapsible urethral catheter
|
US5095915A
(en)
*
|
1990-03-19 |
1992-03-17 |
Target Therapeutics |
Guidewire with flexible distal tip
|
US5257451A
(en)
*
|
1991-11-08 |
1993-11-02 |
Ep Technologies, Inc. |
Method of making durable sleeve for enclosing a bendable electrode tip assembly
|
US5460608A
(en)
*
|
1994-01-25 |
1995-10-24 |
Scimed Life Systems, Inc. |
Kink free catheter
|
SE9404486D0
(sv)
*
|
1994-12-22 |
1994-12-22 |
Astra Ab |
Catheter
|
US5527281A
(en)
*
|
1995-07-27 |
1996-06-18 |
Haas; Joseph A. |
Substitute tip for urethral catheter
|
SE9600276D0
(sv)
|
1996-01-25 |
1996-01-25 |
Astra Ab |
A wetting device for wetting a hydrophilic catheter and a urine collection bag incorporating said device
|
US5965532A
(en)
*
|
1996-06-28 |
1999-10-12 |
Trustees Of Tufts College |
Multivalent compounds for crosslinking receptors and uses thereof
|
EP2305236A1
(en)
|
1997-04-02 |
2011-04-06 |
The Brigham And Women's Hospital, Inc. |
Means of Ascertaining an Individual's Risk Profile for Atherosclerotic Disease
|
PT1096952E
(pt)
|
1998-07-15 |
2008-08-27 |
Brigham & Womens Hospital |
Composições de polissacáridos para a prevenção de infecções causadas por staphylococcus
|
US6368301B1
(en)
|
1999-12-21 |
2002-04-09 |
Advanced Cardiovascular Systems, Inc. |
Catheter having a soft distal tip
|
AU4351201A
(en)
|
2000-03-08 |
2001-09-17 |
Massachusetts Inst Technology |
Heparinase iii and uses thereof
|
JP2003530432A
(ja)
*
|
2000-04-12 |
2003-10-14 |
ミナーヴァ・バイオテクノロジーズ・コーポレーション |
神経変性疾患の治療
|
KR100434720B1
(ko)
*
|
2001-01-03 |
2004-06-07 |
이근호 |
발룬 카테테르의 제조방법
|
US6692461B2
(en)
|
2001-08-07 |
2004-02-17 |
Advanced Cardiovascular Systems, Inc. |
Catheter tip
|
US6918920B1
(en)
*
|
2001-11-01 |
2005-07-19 |
Advanced Cardiovascular Systems, Inc. |
Catheter having an improved distal tip
|
JP4828795B2
(ja)
*
|
2002-03-11 |
2011-11-30 |
モメンタ ファーマシューティカルズ インコーポレイテッド |
硫酸化多糖類の分析
|
CA2477604A1
(en)
|
2002-03-13 |
2003-09-25 |
Signum Biosciences, Inc. |
Modulation of protein methylation and phosphoprotein phosphate
|
US7344505B2
(en)
*
|
2002-10-15 |
2008-03-18 |
Transoma Medical, Inc. |
Barriers and methods for pressure measurement catheters
|
JP2006523226A
(ja)
|
2003-02-28 |
2006-10-12 |
ザ ジョンズ ホプキンス ユニバーシティ |
T細胞調節方法
|
AU2004248187A1
(en)
|
2003-06-12 |
2004-12-23 |
University Of Colorado System Technology |
Systems and methods for treating human inflammatory and proliferative diseases and wounds, with fatty acid metabolism inhibitors and/or glycolytic inhibitors
|
JP2007502991A
(ja)
|
2003-08-20 |
2007-02-15 |
バイオサイト インコーポレイテッド |
生物活性ナトリウム利尿ペプチドを測定するための、およびその治療可能性を向上させるための方法および組成物
|
US7655000B2
(en)
*
|
2003-09-26 |
2010-02-02 |
Tyco Healthcare Group Lp |
Urology catheter
|
US7972350B2
(en)
*
|
2004-01-29 |
2011-07-05 |
Boston Scientific Scimed, Inc. |
Catheter tip
|
JP5230865B2
(ja)
|
2004-07-15 |
2013-07-10 |
テトラロジック ファーマシューティカルズ コーポレーション |
Iap結合性化合物
|
US8299083B2
(en)
|
2004-08-17 |
2012-10-30 |
The Johns Hopkins University |
PDE5 inhibitor compositions and methods for treating cardiac indications
|
US7893034B2
(en)
|
2004-09-02 |
2011-02-22 |
Yale University |
Regulation of oncogenes by microRNAs
|
WO2006034454A1
(en)
*
|
2004-09-23 |
2006-03-30 |
The Trustees Of The University Of Princeton |
Bcl-2 family member and bh-3 only proteins for use in development of peptidomimetics
|
EP2927693A1
(en)
|
2004-10-06 |
2015-10-07 |
The Brigham and Women's Hospital |
Relevance of achieved levels of markers of systemic inflammation following treatment
|
WO2006052940A2
(en)
*
|
2004-11-05 |
2006-05-18 |
Asthmatx, Inc. |
Medical device with procedure improvement features
|
EP1843734A4
(en)
|
2005-02-03 |
2008-09-10 |
Signum Biosciences Inc |
COMPOSITIONS AND METHODS FOR ENHANCING COGNITIVE FUNCTION
|
US7923041B2
(en)
|
2005-02-03 |
2011-04-12 |
Signum Biosciences, Inc. |
Compositions and methods for enhancing cognitive function
|
US8841259B2
(en)
*
|
2005-02-24 |
2014-09-23 |
Joslin Diabetes Center |
Compositions and methods for treating vascular permeability
|
AU2006216450C1
(en)
*
|
2005-02-25 |
2013-01-10 |
Medivir Ab |
Dimeric IAP inhibitors
|
US8354384B2
(en)
*
|
2005-06-23 |
2013-01-15 |
Yale University |
Anti-aging micrornas
|
EP1906972B1
(en)
|
2005-07-19 |
2013-09-11 |
The University of Tennessee Research Foundation |
LPA2 receptor agonist for treating diarrhea
|
JP2009502954A
(ja)
|
2005-07-27 |
2009-01-29 |
ユニバーシティ オブ フロリダ リサーチ ファウンデーション,インコーポレイティド |
タンパク質のミスフォールディングを修正する小分子及びその使用
|
US20100256046A1
(en)
*
|
2009-04-03 |
2010-10-07 |
Tetralogic Pharmaceuticals Corporation |
Treatment of proliferative disorders
|
JP2009509128A
(ja)
*
|
2005-08-09 |
2009-03-05 |
テトラロジック ファーマシューティカルズ コーポレーション |
増殖性疾患の治療
|
US20080021198A1
(en)
*
|
2005-10-12 |
2008-01-24 |
Yigong Shi |
Modulators of protein phosphatase 2A and PP2A methyl esterase
|
US8658608B2
(en)
*
|
2005-11-23 |
2014-02-25 |
Yale University |
Modified triple-helix forming oligonucleotides for targeted mutagenesis
|
WO2007064997A2
(en)
*
|
2005-12-01 |
2007-06-07 |
University Of Pittsburgh Of The Commonwealth System Of Higher Education |
Compounds and methods for inhibiting apoptosis
|
US20100056495A1
(en)
*
|
2006-07-24 |
2010-03-04 |
Tetralogic Pharmaceuticals Corporation |
Dimeric iap inhibitors
|
WO2008014238A2
(en)
*
|
2006-07-24 |
2008-01-31 |
Tetralogic Pharmaceuticals Corporation |
Dimeric iap inhibitors
|
US8143426B2
(en)
*
|
2006-07-24 |
2012-03-27 |
Tetralogic Pharmaceuticals Corporation |
IAP inhibitors
|
WO2008014240A2
(en)
|
2006-07-24 |
2008-01-31 |
Tetralogic Pharmaceuticals Corporation |
Dimeric iap inhibitors
|
EP2049563B1
(en)
*
|
2006-07-24 |
2014-03-12 |
Tetralogic Pharmaceuticals Corporation |
Dimeric iap antagonists
|
US20080153773A1
(en)
*
|
2006-08-08 |
2008-06-26 |
Yigong Shi |
Modulators of phosphotyrosyl phosphatase activator
|
WO2008060791A2
(en)
*
|
2006-10-13 |
2008-05-22 |
The Trustees Of The University Of Princeton |
Modulators of protein phosphatase 2a
|
US7645616B2
(en)
*
|
2006-10-20 |
2010-01-12 |
The University Of Hong Kong |
Use of lipocalin-2 as a diagnostic marker and therapeutic target
|
CA2674493C
(en)
|
2007-01-05 |
2017-05-09 |
Massachusetts Institute Of Technology |
Compositions of and methods of using sulfatases from flavobacterium heparinum
|
EP2099911A2
(en)
*
|
2007-01-11 |
2009-09-16 |
Yale University |
Compositions and methods for targeted inactivation of hiv cell surface receptors
|
US20100119474A1
(en)
*
|
2007-03-06 |
2010-05-13 |
Cornell University |
Chronic obstructive pulmonary disease susceptibility and related compositions and methods
|
US20100111943A1
(en)
*
|
2007-03-22 |
2010-05-06 |
Medical College Of Georgia Research Institute, Inc |
Compositions and methods for inhibiting cancer metastasis
|
WO2008122039A2
(en)
*
|
2007-04-02 |
2008-10-09 |
The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Selenocysteine mediated hybrid antibody molecules
|
US9139876B1
(en)
|
2007-05-03 |
2015-09-22 |
Momenta Pharmacueticals, Inc. |
Method of analyzing a preparation of a low molecular weight heparin
|
EP2559773B1
(en)
|
2007-06-08 |
2015-04-22 |
The Government of the United States of America as represented by the Secretary of the Department of Health and Human Services |
Methods for determining a hepatocellular carcinoma subtype
|
US20090274682A1
(en)
*
|
2008-02-05 |
2009-11-05 |
The Trustees Of Princeton University |
Demethylation and inactivation of protein phosphatase 2a
|
WO2009108745A1
(en)
*
|
2008-02-26 |
2009-09-03 |
The Trustees Of Princeton University |
Structure of a protein phosphatase 2a holoenzyme: insights into tau dephosphorylation
|
AU2009244267A1
(en)
*
|
2008-05-07 |
2009-11-12 |
Abraxis Bioscience, Llc |
Enhancement of drug therapy by miRNA
|
US20100146875A1
(en)
*
|
2008-05-30 |
2010-06-17 |
John Redding |
Support post structure
|
WO2010017103A2
(en)
*
|
2008-08-04 |
2010-02-11 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Servic |
Fully human anti-human nkg2d monoclonal antibodies
|
JP2012503004A
(ja)
|
2008-09-17 |
2012-02-02 |
テトラロジック ファーマシューティカルズ コーポレーション |
Iap阻害剤
|
US8729053B2
(en)
*
|
2008-09-22 |
2014-05-20 |
The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services |
Nuclear factor kappa B pathway inhibitor composition and use of same
|
WO2010075417A1
(en)
|
2008-12-23 |
2010-07-01 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Survivin specific t cell receptor for treating cancer
|
WO2010075303A1
(en)
|
2008-12-23 |
2010-07-01 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Splicing factors with a puf protein rna-binding domain and a splicing effector domain and uses of same
|
US8309356B2
(en)
*
|
2009-04-01 |
2012-11-13 |
Yale University |
Pseudocomplementary oligonucleotides for targeted gene therapy
|
AU2010238723A1
(en)
|
2009-04-23 |
2011-11-10 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Anti-human ROR1 antibodies
|
EP3375441A1
(en)
|
2009-04-30 |
2018-09-19 |
The U.S.A. as represented by the Secretary, Department of Health and Human Services |
Schweinfurthins and uses thereof
|
US8877199B2
(en)
|
2009-05-15 |
2014-11-04 |
The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services |
B cell surface reactive antibodies
|
IN2012DN00352A
(en])
|
2009-06-16 |
2015-08-21 |
Bikam Pharmaceuticals Inc |
|
US8283372B2
(en)
|
2009-07-02 |
2012-10-09 |
Tetralogic Pharmaceuticals Corp. |
2-(1H-indol-3-ylmethyl)-pyrrolidine dimer as a SMAC mimetic
|
WO2011011797A2
(en)
|
2009-07-24 |
2011-01-27 |
The Board Of Trustees Of The Leland Stanford Junior University |
Cytokine compositions and methods of use thereof
|
EP2287304A1
(en)
|
2009-08-17 |
2011-02-23 |
Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. |
Novel treatment of patients after stent implantation or balloon dilatation and novel drug eluting stents
|
EP2483301A1
(en)
|
2009-10-01 |
2012-08-08 |
The United States Of America, As Represented By The Secretary, Department of Health and Human Services |
Anti-vascular endothelial growth factor receptor-2 chimeric antigen receptors and use of same for the treatment of cancer
|
ES2817779T3
(es)
*
|
2010-01-19 |
2021-04-08 |
Momenta Pharmaceuticals Inc |
Evaluación de preparaciones de heparina
|
US20110293585A1
(en)
|
2010-04-21 |
2011-12-01 |
Helix Therapeutics, Inc. |
Compositions and methods for treatment of lysosomal storage disorders
|
US20110262406A1
(en)
|
2010-04-21 |
2011-10-27 |
Yale University |
Compositions and methods for targeted inactivation of hiv cell surface receptors
|
WO2012012627A1
(en)
|
2010-07-22 |
2012-01-26 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Method of preventing or treating viral infection
|
AU2011336650B2
(en)
|
2010-12-01 |
2016-12-08 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Chimeric rabbit/human ROR1 antibodies
|
JP2014506789A
(ja)
|
2011-02-03 |
2014-03-20 |
マーナ セラピューティクス インコーポレイテッド |
miR−124の合成模倣体
|
MX342927B
(es)
|
2011-02-03 |
2016-10-19 |
Mirna Therapeutics Inc |
Mimeticos sinteticos de mir-34.
|
WO2012115952A1
(en)
|
2011-02-21 |
2012-08-30 |
Momenta Pharmaceuticals, Inc. |
Evaluating heparin preparations
|
WO2012125623A2
(en)
|
2011-03-14 |
2012-09-20 |
Ludwig Institute For Cancer Research Ltd. |
Cleavage inhibitors of transforming growth factor beta type i receptor and uses thereof in cancer therapy
|
US9266960B2
(en)
|
2011-04-08 |
2016-02-23 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Anti-epidermal growth factor receptor variant III chimeric antigen receptors and use of same for the treatment of cancer
|
BR112013027057A2
(pt)
|
2011-04-21 |
2020-08-11 |
Trustees Of Tufts College |
composições e métodos para a estabilização de agentes ativos
|
US9133082B2
(en)
|
2011-06-14 |
2015-09-15 |
Bikam Pharmaceuticals, Inc. |
Opsin-binding ligands, compositions and methods of use
|
US9593160B2
(en)
|
2011-07-18 |
2017-03-14 |
President And Fellows Of Harvard College |
Engineered microbe-targeting molecules and uses thereof
|
EP2739734A1
(en)
|
2011-08-03 |
2014-06-11 |
The Charlotte-Mecklenburg Hospital Authority d/b/a Carolina Healthcare System |
Treatment of fibrosis using microrna-19b
|
AU2012325341B2
(en)
|
2011-10-19 |
2017-01-05 |
Bikam Pharmaceuticals, Inc. |
Opsin-binding ligands, compositions and methods of use
|
CN109485730A
(zh)
|
2011-10-20 |
2019-03-19 |
美国卫生和人力服务部 |
抗cd22嵌合抗原受体
|
EP2785346A4
(en)
|
2011-11-30 |
2015-04-29 |
Bikam Pharmaceuticals Inc |
OPSINBINDING LIGANDS, COMPOSITIONS THEREOF, AND METHOD OF USE THEREOF
|
BR112014013106A2
(pt)
|
2011-12-01 |
2017-06-13 |
Bikam Pharmaceuticals Inc |
ligantes de ligação à opsina, composições e métodos de uso
|
CA3209571A1
(en)
|
2012-03-23 |
2013-09-26 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Anti-mesothelin chimeric antigen receptors
|
AU2013252785B2
(en)
|
2012-04-27 |
2017-05-11 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Use of CpG oligonucleotides co-formulated with an antibiotic to accelarate wound healing
|
CN110511278B
(zh)
|
2012-05-07 |
2024-08-09 |
达特茅斯大学理事会 |
抗b7-h6抗体、融合蛋白及其使用方法
|
US9119858B2
(en)
|
2012-08-21 |
2015-09-01 |
Genesys Research Institute, Inc. |
Compositions and methods for treating or preventing anthracycline induced cardiotoxicity
|
AU2013335180B2
(en)
|
2012-10-24 |
2018-07-12 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
M971 chimeric antigen receptors
|
EP2931273A1
(en)
|
2012-12-12 |
2015-10-21 |
The Charlotte-Mecklenburg Hospital Authority D/B/A Carolinas Healthcare System |
Methods of treating portal hypertension
|
WO2014093711A1
(en)
|
2012-12-12 |
2014-06-19 |
The Charlotte-Mecklenburg Hospital Authority D/B/A Carolinas Healthcare System |
Methods of treating hepatic fibrosis and associated diseases by regulating rev-erb activity
|
ES2872403T3
(es)
|
2013-03-14 |
2021-11-02 |
Childrens Medical Center |
Péptido Psap para el tratamiento de cánceres que expresan CD36
|
US11376329B2
(en)
|
2013-03-15 |
2022-07-05 |
Trustees Of Tufts College |
Low molecular weight silk compositions and stabilizing silk compositions
|
EP2970411B1
(en)
|
2013-03-15 |
2018-05-09 |
Trustees Of Tufts College |
Low molecular weight silk compositions and stabilizing silk compositions
|
WO2014160627A1
(en)
|
2013-03-25 |
2014-10-02 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Anti-cd276 polypeptides, proteins, and chimeric antigen receptors
|
US20160052985A1
(en)
|
2013-04-04 |
2016-02-25 |
Ieo - Istituto Europeo Di Oncologia Srl |
Thymic stromal lymphopoietin fragments and uses thereof
|
US10274503B2
(en)
|
2013-05-08 |
2019-04-30 |
Vegenics Pty Limited |
Methods of using VEGF-C biomarkers for age-related macular degeneration (AMD) diagnosis
|
KR20200108903A
(ko)
|
2013-06-25 |
2020-09-21 |
더 월터 앤드 엘리자 홀 인스티튜트 오브 메디컬 리서치 |
세포내 감염의 치료 방법
|
WO2015006543A1
(en)
|
2013-07-10 |
2015-01-15 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Method for predicting and detecting tumor metastasis in kidney cancer
|
WO2015061361A1
(en)
|
2013-10-21 |
2015-04-30 |
Salk Institute For Biological Studies |
Mutated fibroblast growth factor (fgf) 1 and methods of use
|
SG11201604565WA
(en)
|
2013-12-06 |
2016-07-28 |
Us Health |
Thymic stromal lymphopoietin receptor-specific chimeric antigen receptors and methods using same
|
EP3083658B1
(en)
|
2013-12-18 |
2019-05-08 |
President and Fellows of Harvard College |
Crp capture/detection of gram positive bacteria
|
CN113908253A
(zh)
|
2014-03-26 |
2022-01-11 |
儿童医学中心公司 |
环状鞘脂激活蛋白原肽及其用途
|
US11918695B2
(en)
|
2014-05-09 |
2024-03-05 |
Yale University |
Topical formulation of hyperbranched polymer-coated particles
|
WO2015172153A1
(en)
|
2014-05-09 |
2015-11-12 |
Yale University |
Topical formulation of hyperbranched polyglycerol-coated particles thereof
|
ES2875057T3
(es)
|
2014-09-17 |
2021-11-08 |
Us Health |
Anticuerpos anti-CD276 (B7H3)
|
WO2016079527A1
(en)
|
2014-11-19 |
2016-05-26 |
Tetralogic Birinapant Uk Ltd |
Combination therapy
|
WO2016097773A1
(en)
|
2014-12-19 |
2016-06-23 |
Children's Cancer Institute |
Therapeutic iap antagonists for treating proliferative disorders
|
US10744157B2
(en)
|
2015-03-26 |
2020-08-18 |
The Trustees Of Dartmouth College |
Anti-MICA antigen binding fragments, fusion molecules, cells which express and methods of using
|
BR112017026209A2
(pt)
|
2015-06-05 |
2018-11-27 |
Ibio, Inc. |
fragmentos e variantes de endostatinas para uso no tratamento de fibrose
|
EP3831844B1
(en)
|
2015-06-26 |
2024-03-13 |
Prindex S.r.l. |
Diagnosis and therapy of multiple sclerosis
|
US10973912B2
(en)
|
2015-06-29 |
2021-04-13 |
President And Fellows Of Harvard College |
Treatment for myopathy
|
CN108289928B
(zh)
|
2015-08-06 |
2024-09-17 |
哈佛大学校长及研究员协会 |
改进的微生物-结合分子和其用途
|
AU2017209313A1
(en)
|
2016-01-20 |
2018-08-09 |
The Scripps Research Institute |
ROR2 antibody compositions and related methods
|
AU2017210327A1
(en)
|
2016-01-20 |
2018-08-09 |
Nbe-Therapeutics Ag |
ROR1 antibody compositions and related methods
|
AU2017221405A1
(en)
|
2016-02-16 |
2018-09-20 |
Carnegie Mellon University |
Compositions for enhancing targeted gene editing and methods of use thereof
|
US20200308590A1
(en)
|
2016-02-16 |
2020-10-01 |
Yale University |
Compositions and methods for treatment of cystic fibrosis
|
MX2018012719A
(es)
|
2016-04-19 |
2019-05-30 |
Us Health |
Ram negativas para tratar la dermatitis atopica.
|
US10293005B2
(en)
|
2016-04-19 |
2019-05-21 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Use of gram negative species to treat atopic dermatitis
|
BR112018073414A2
(pt)
|
2016-05-16 |
2019-08-27 |
Checkmab S R L |
molécula, composição farmacêutica, e, métodos in vitro para prognosticar e/ou diagnosticar e/ou avaliar o risco de desenvolver e/ou para monitorar a progressão e/ou para monitorar a eficácia de um tratamento terapêutico e/ou para a triagem de um tratamento terapêutico de um tumor, para tratar e/ou prevenir tumor e para identificar uma molécula.
|
EP3464366A1
(en)
|
2016-05-27 |
2019-04-10 |
The U.S.A. As Represented By The Secretary, Department Of Health And Human Services |
Flt3-specific chimeric antigen receptors and methods using same
|
WO2017207623A1
(en)
|
2016-05-31 |
2017-12-07 |
Université de Lausanne |
Mirna as biomarkers and regulators of cancer stem cells
|
US20190322643A1
(en)
|
2016-06-29 |
2019-10-24 |
Georgia State University Research Foundation, Inc. |
Histone deacetylase and histone methyltransferase inhibitors and methods of making and use of the same
|
US20190201414A1
(en)
|
2016-07-01 |
2019-07-04 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Serv |
Inhibitor of heme degradation for use to improve antibiotic treatment of mycobacterium tuberculosis infection
|
CA3056797A1
(en)
|
2017-03-16 |
2018-09-20 |
Children's Medical Center Corporation |
Engineered liposomes as cancer-targeted therapeutics
|
US20200113821A1
(en)
|
2017-04-04 |
2020-04-16 |
Yale University |
Compositions and methods for in utero delivery
|
AU2018258466B2
(en)
|
2017-04-25 |
2025-05-22 |
Prothera Biologics, Inc. |
Methods for quantifying inter-alpha inhibitor proteins
|
CA3099487A1
(en)
|
2017-07-20 |
2019-01-24 |
Nbe-Therapeutics Ag |
Human antibodies binding to ror2
|
JP6817492B2
(ja)
|
2017-08-07 |
2021-01-20 |
エヌビーイー セラピューティクス アクチェン ゲゼルシャフト |
高いインビボ忍容性を有するアントラサイクリン系の抗体薬物複合体
|
WO2019154884A1
(en)
|
2018-02-07 |
2019-08-15 |
Ecole Polytechnique Federale De Lausanne (Epfl) |
Method for determining cancer invasiveness and patient prognosis
|
JP2021523900A
(ja)
|
2018-05-11 |
2021-09-09 |
フォルテ サブシディアリー,インク. |
皮膚疾病の処置のための組成物
|
KR20210095132A
(ko)
|
2018-10-04 |
2021-07-30 |
럿거스, 더 스테이트 유니버시티 오브 뉴 저지 |
뉴로메딘 펩티드를 이용하여 2형 사이토카인 매개 염증을 감소시키는 방법
|
WO2020081737A1
(en)
|
2018-10-16 |
2020-04-23 |
Massachusetts Institute Of Technology |
Compositions and methods for inducing intestinal stem cell regeneration
|
EP3867365A1
(en)
|
2018-10-19 |
2021-08-25 |
Board of Regents, The University of Texas System |
Engineered long interspersed element (line) transposons and methods of use thereof
|
EP3677693A1
(en)
|
2019-01-03 |
2020-07-08 |
Ecole Polytechnique Federale De Lausanne (EPFL) EPFL-TTO |
Transpochimeric gene trancripts (tcgts) as cancer biomarkers
|
SG11202107708XA
(en)
|
2019-01-18 |
2021-08-30 |
Janssen Biotech Inc |
Gprc5d chimeric antigen receptors and cells expressing the same
|
BR112021014657A2
(pt)
|
2019-01-30 |
2021-09-21 |
Janssen Pharmaceutica N.V. |
Métodos para tratar câncer de próstata com base em subtipos moleculares
|
WO2020186187A1
(en)
|
2019-03-13 |
2020-09-17 |
University Of Pittsburgh - Of The Commonwealth System Of Higher Education |
Methods for treating bladder and urethra dysfunction and disease
|
CA3136618A1
(en)
|
2019-04-10 |
2020-10-15 |
Elevatebio Technologies, Inc. |
Flt3-specific chimeric antigen receptors and methods of using the same
|
AU2020280105A1
(en)
|
2019-05-22 |
2022-01-20 |
Massachusetts Institute Of Technology |
Circular RNA compositions and methods
|
WO2020239478A1
(en)
|
2019-05-28 |
2020-12-03 |
Pharma Mar, S.A. |
Trabectedin for treating sarcomas based on genomic markers
|
US20220243211A1
(en)
|
2019-06-21 |
2022-08-04 |
Yale University |
Peptide nucleic acid compositions with modified hoogsteen binding segments and methods of use thereof
|
WO2020257779A1
(en)
|
2019-06-21 |
2020-12-24 |
Yale University |
Hydroxymethyl-modified gamma-pna compositions and methods of use thereof
|
EP4004057A1
(en)
|
2019-07-26 |
2022-06-01 |
Janssen Biotech, Inc. |
Proteins comprising kallikrein related peptidase 2 antigen binding domains and their uses
|
CN114174346B
(zh)
|
2019-07-26 |
2025-08-01 |
詹森生物科技公司 |
抗hk2嵌合抗原受体(car)
|
US20220280656A1
(en)
|
2019-07-31 |
2022-09-08 |
Yale University |
Compositions and methods for treating sickle cell disease
|
CN112390894A
(zh)
|
2019-08-12 |
2021-02-23 |
广东东阳光药业有限公司 |
嵌合抗原受体及其应用
|
CA3151344A1
(en)
|
2019-08-16 |
2021-02-25 |
Janssen Biotech, Inc. |
Therapeutic immune cells with improved function and methods for making the same
|
PE20221273A1
(es)
|
2019-11-18 |
2022-09-01 |
Janssen Biotech Inc |
Receptores del antigeno quimerico anti-cd79, celulas car-t, y usos de estos
|
IL271778A
(en)
|
2019-12-31 |
2021-06-30 |
Ichilov Tech Ltd |
Methods for treating atopic dermatitis
|
EP3868396A1
(en)
|
2020-02-20 |
2021-08-25 |
Enthera S.R.L. |
Inhibitors and uses thereof
|
PE20240020A1
(es)
|
2020-03-13 |
2024-01-04 |
Janssen Biotech Inc |
Materiales y metodos para la union de siglec-3/cd33
|
WO2021225781A2
(en)
|
2020-05-07 |
2021-11-11 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Aberrant post-translational modifications (ptms) in methyl- and propionic acidemia and a mutant sirtuin (sirt) to metabolize ptms
|
WO2021236855A1
(en)
|
2020-05-19 |
2021-11-25 |
Orna Therapeutics, Inc. |
Circular rna compositions and methods
|
TW202212354A
(zh)
|
2020-08-03 |
2022-04-01 |
美商健生生物科技公司 |
用於病毒治療劑中之多向生物運輸的材料及方法
|
CN112295084B
(zh)
*
|
2020-09-25 |
2023-03-28 |
池州市琼琚信息技术服务有限公司 |
一种热收缩膜固定胶水形状的方法
|
US20240042053A1
(en)
|
2020-10-16 |
2024-02-08 |
University Of Georgia Research Foundation, Inc. |
Glycoconjugates
|
EP4059498A1
(en)
|
2021-03-16 |
2022-09-21 |
Centre Hospitalier Universitaire Vaudois (CHUV) |
Methods and compositions for treating conditions associated with hypermineralization
|
JP2024512035A
(ja)
|
2021-03-24 |
2024-03-18 |
ヤンセン バイオテツク,インコーポレーテツド |
Cd22及びcd79bを標的とする抗体
|
WO2022237974A1
(en)
|
2021-05-12 |
2022-11-17 |
Ecole Polytechnique Federale De Lausanne (Epfl) |
Krab-containing zinc finger protein and cancer
|
CN115404240A
(zh)
|
2021-05-28 |
2022-11-29 |
上海环码生物医药有限公司 |
制备环形rna的构建体、方法及其用途
|
US20240279687A1
(en)
|
2021-06-07 |
2024-08-22 |
Yale University |
Peptide nucleic acids for spatiotemporal control of crispr-cas binding
|
WO2022271955A1
(en)
|
2021-06-23 |
2022-12-29 |
Musc Foundation For Research Development |
Novel targeted shrna nanoparticles for cancer therapy
|
US12129302B2
(en)
|
2021-08-25 |
2024-10-29 |
Ibio, Inc. |
Anti-CD-25 antibody
|
US20250019455A1
(en)
|
2021-09-24 |
2025-01-16 |
Pharmaceutica Nv |
Proteins comprising cd20 binding domains, and uses thereof
|
IL312490A
(en)
|
2021-11-08 |
2024-07-01 |
Orna Therapeutics Inc |
Lipid nanoparticle compositions for delivering circular polynucleotides
|
EP4532731A2
(en)
|
2022-05-30 |
2025-04-09 |
Shanghai Circode Biomed Co., Ltd |
Synthetic circular rna compositions and methods of use thereof
|
US12297285B2
(en)
|
2022-06-24 |
2025-05-13 |
Orna Therapeutics, Inc. |
Circular RNA encoding chimeric antigen receptors targeting BCMA
|
WO2024094526A1
(en)
|
2022-11-02 |
2024-05-10 |
Ecole Polytechnique Federale De Lausanne (Epfl) |
6-diazo-5-oxo-l-norleucine prodrugs
|
WO2024102762A1
(en)
|
2022-11-08 |
2024-05-16 |
Orna Therapeutics, Inc. |
Lipids and lipid nanoparticle compositions for delivering polynucleotides
|
WO2024102730A1
(en)
|
2022-11-08 |
2024-05-16 |
Orna Therapeutics, Inc. |
Lipids and nanoparticle compositions for delivering polynucleotides
|
AU2023398825A1
(en)
|
2022-12-15 |
2025-06-26 |
Orna Therapeutics, Inc. |
Circular rna compositions and methods
|
WO2024205657A2
(en)
|
2023-03-29 |
2024-10-03 |
Orna Therapeutics, Inc. |
Lipids and lipid nanoparticle compositions for delivering polynucleotides
|
WO2024233308A2
(en)
|
2023-05-05 |
2024-11-14 |
Orna Therapeutics, Inc. |
Circular rna compositions and methods
|
WO2024263649A1
(en)
|
2023-06-19 |
2024-12-26 |
Yale University |
Methods and compositions for enrichment and sequencing of expansion-specific rna transcripts
|
WO2025007148A1
(en)
|
2023-06-30 |
2025-01-02 |
Orna Therapeutics, Inc. |
Polymer lipid nanoparticle compositions for delivering circular polynucleotides
|
WO2025021993A1
(en)
|
2023-07-27 |
2025-01-30 |
Omnilinx Therapeutics Ag |
Endocytic and scavenger receptor-targeting chimeric proteins and uses thereof
|
WO2025049690A1
(en)
|
2023-08-29 |
2025-03-06 |
Orna Therapeutics, Inc. |
Circular polyethylene glycol lipids
|
EP4537907A1
(en)
|
2023-10-10 |
2025-04-16 |
Enthera S.r.l. |
Cd248 inhibitors and uses thereof
|
WO2025117969A1
(en)
|
2023-12-01 |
2025-06-05 |
Orna Therapeutics, Inc. |
Process for manufacturing lipid nanoparticles
|